Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
ALBIREO PHARMA, INC. (ALBO)
|
Add to portfolio |
|
|
|
| Price: |
$32.57
| | Metrics |
| OS: |
20.7
|
M
| |
-131
|
% ROE
|
| Market cap: |
$674
|
M
| |
-219
|
% ROIC
|
|
Net cash:
|
$222
|
M
| |
$10.75
|
per share
|
|
EV:
|
$452
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($122)
|
M
| |
|
|
|
EBIT
|
($123)
|
M
| |
|
|
| EPS |
($6.72)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Sep-30-16 | Dec-31-15 |
| Revenues | 40.6 | 8.3 | 9.6 | 12.7 | 0.0 | 11.4 | 0.0 | 5.1 |
| Revenue growth | 388.4% | -13.8% | -24.4% | 1273900.0% | -100.0% | 122.9% | | |
| Cost of goods sold | 1.4 | 0.0 | 0.0 | 0.0 | 0.0 | -24.8 | 0.0 | 1.6 |
| Gross profit | 39.2 | 8.3 | 9.6 | 12.7 | 0.0 | 36.2 | 0.0 | 3.5 |
| Gross margin | 96.7% | 100.0% | 100.0% | 100.0% | 100.0% | 318.6% | | 68.4% |
| Selling, general and administrative | 69.6 | 42.4 | | | | | | |
| Research and development | 82.5 | 76.8 | 45.6 | 31.7 | 13.0 | 8.1 | 3.7 | 5.6 |
| General and administrative | | | 23.0 | 18.1 | 15.2 | 15.8 | 10.3 | 4.5 |
| EBITA | -20.1 | -96.3 | -61.1 | -37.9 | -24.6 | -11.1 | 14.0 | -4.7 |
| EBITA margin | -49.5% | -1158.8% | -634.2% | -297.4% | -2457700.0% | -97.7% | | -92.7% |
| Amortization of intangibles | | | | | | | 0.0 | |
| EBIT | -20.1 | -96.3 | -61.1 | -37.9 | -24.6 | -11.1 | 14.0 | -4.7 |
| EBIT margin | -49.5% | -1158.8% | -634.2% | -297.4% | -2457700.0% | -97.7% | | -92.7% |
| Pre-tax income | -34.0 | -107.6 | -62.7 | -46.1 | -24.2 | -16.3 | 13.7 | -6.8 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.1 | 0.1 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | | | | 0.4% | 0.0% |
| Net income | -34.0 | -107.6 | -62.7 | -46.1 | -24.4 | -16.4 | -13.8 | -6.8 |
| Net margin | -83.9% | -1295.5% | -650.9% | -361.9% | -2441400.0% | -143.9% | | -132.7% |
| |
| Diluted EPS | ($1.77) | ($6.73) | ($5.04) | ($3.94) | ($3.12) | ($13.19) | ($6.45) | ($25.49) |
| Shares outstanding (diluted) | 19.2 | 16.0 | 12.4 | 11.7 | 7.8 | 1.2 | 2.1 | 0.3 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|